An interesting observation: prolonged green urine can be a combined effect of decreased liver and renal function in a patient with heart failure-a case report

Basit Öğe Kaydı
dc.authoridColluoglu, Tugce/0000-0002-2227-6177
dc.contributor.authorCoellueoglu, Tugce
dc.contributor.authorAksu, Melahat Hicran
dc.contributor.authorOenalan, Orhan
dc.contributor.authorAkin, Yesim
dc.date.accessioned2024-09-29T16:03:07Z
dc.date.available2024-09-29T16:03:07Z
dc.date.issued2023
dc.departmentKarabük Üniversitesien_US
dc.description.abstractBackground The administration of propofol and methylene blue (MB) can be associated with the appearance of prolonged green urine discoloration, particularly in patients with heart failure (HF) concomitant with renal and liver dysfunction. Understanding the reasons behind this phenomenon is of clinical significance.Case summary A 79-year-old woman with a history of HF experienced dyspnoea and persistent green urine discoloration for a week, leading to her hospitalization for acutely decompensated HF. A recent dual-chamber rate-modulated-pacemaker implantation had necessitated propofol sedation and the administration of 100 mg of MB due to methaemoglobinaemia. Upon admission, the patient exhibited elevated levels of brain natriuretic peptide (BNP) and liver function tests, as well as a significant decrease in glomerular filtration rate (GFR). Initial therapy with intravenous furosemide yielded an inadequate response, requiring the initiation of combined diuretic therapy (CDT). The patient's condition improved with CDT, resulting in the normalization of BNP, liver function tests, and GFR, along with the restoration of normal urine colour lasting 12 days.Discussion Our case report sheds light on the complex interaction between drug metabolic pathways and their potential for prolonged side effects, particularly in patients with multiorgan dysfunction. The association between propofol, MB, and green urine discoloration in the context of HF warrants further investigation, emphasizing the need for increased awareness of drug interactions and their implications in complex clinical scenarios.en_US
dc.identifier.doi10.1093/ehjcr/ytad570
dc.identifier.issn2514-2119
dc.identifier.issue12en_US
dc.identifier.pmid38089126en_US
dc.identifier.scopus2-s2.0-85180083708en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1093/ehjcr/ytad570
dc.identifier.urihttps://hdl.handle.net/20.500.14619/5912
dc.identifier.volume7en_US
dc.identifier.wosWOS:001120070600003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofEuropean Heart Journal-Case Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGreen urineen_US
dc.subjectHeart failureen_US
dc.subjectMultiorgan dysfunctionen_US
dc.subjectMethylene blueen_US
dc.subjectPropofolen_US
dc.subjectCase reporten_US
dc.titleAn interesting observation: prolonged green urine can be a combined effect of decreased liver and renal function in a patient with heart failure-a case reporten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu